Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis
出版年份 2022 全文链接
标题
Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 10, Pages 5533
出版商
MDPI AG
发表日期
2022-05-17
DOI
10.3390/ijms23105533
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse
- (2021) Long T. Nguyen et al. Scientific Reports
- An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
- (2021) Alison Findlay et al. Clinical and Translational Medicine
- Inhibition of lysyl oxidase ameliorates renal injury by inhibiting CD44-mediated pericyte detachment and loss of peritubular capillaries
- (2020) Mohd Aslam Saifi et al. LIFE SCIENCES
- Lysyl Oxidase Directly Contributes to Extracellular Matrix Production and Fibrosis in Systemic Sclerosis.
- (2020) Xinh-Xinh Mina Nguyen et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Linking LOXL2 to Cardiac Interstitial Fibrosis
- (2020) Melisse Erasmus et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Significance of nuclear LOXL2 inhibition in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome
- (2020) Ayako Matsuo et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Co-administration of resveratrol and beta-aminopropionitrile attenuates liver fibrosis development via targeting lysyl oxidase in CCl4-induced liver fibrosis in rats
- (2019) Roohollah Mohseni et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice
- (2019) Orly Leiva et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3
- (2019) Alison D. Findlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through LOXL4: New Evidence from 3D Skin‐like Tissues
- (2019) Mengqi Huang et al. Arthritis & Rheumatology
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy
- (2018) Stefanie Stangenberg et al. Scientific Reports
- The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis
- (2018) Heidi Schilter et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
- (2017) Naoki Ikenaga et al. GUT
- The Role of the Lysyl Oxidases in Tissue Repair and Remodeling: A Concise Review
- (2017) Linyi Cai et al. Tissue Engineering and Regenerative Medicine
- The Role of the Lysyl Oxidases in Tissue Repair and Remodeling: A Concise Review
- (2017) Linyi Cai et al. Tissue Engineering and Regenerative Medicine
- Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
- (2017) Ganesh Raghu et al. Lancet Respiratory Medicine
- Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis
- (2017) Verena Aumiller et al. Scientific Reports
- Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial
- (2016) Eric G. Meissner et al. LIVER INTERNATIONAL
- Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment
- (2016) Jin Yang et al. Nature Communications
- Matrix remodeling in systemic sclerosis
- (2015) Andrew Leask Seminars in Immunopathology
- Treatment of rapidly progressive systemic sclerosis: current and futures perspectives
- (2015) Fabian A Mendoza et al. Expert Opinion on Orphan Drugs
- Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review
- (2014) Nickolay Fedchenko et al. Diagnostic Pathology
- Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis
- (2014) Amiq Gazdhar et al. Scientific Reports
- Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression
- (2013) J. W. Chien et al. EUROPEAN RESPIRATORY JOURNAL
- Brief Report: Lysyl Oxidase Is a Potential Biomarker of Fibrosis in Systemic Sclerosis
- (2013) Doron Rimar et al. Arthritis & Rheumatology
- Activated protein C improves left ventricular remodelling after ischemia–reperfusion injury in rats
- (2012) W.N. Lay et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Animal models of systemic sclerosis: Prospects and limitations
- (2010) Christian Beyer et al. ARTHRITIS AND RHEUMATISM
- Standardized quantification of pulmonary fibrosis in histological samples
- (2008) Ralf-Harto Hübner et al. BIOTECHNIQUES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More